Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.84 |
| ▸ | CCR5 | P51681 | 2/20 | 0.84 |
| ▸ | CCR8 | P51685 | 2/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.84 |
| ▸ | METAP2 | P50579 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abametapir SCHEMBL29374261 | 0.92 | CCR1 (1.00) | CCR1CCR5CCR8HDAC6METAP2 | |
| Abametapir SCHEMBL351152 | 0.92 | CCR1 (1.00) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL17051503 | 0.91 | CCR1 (0.70) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL21170481 | 0.87 | CCR1 (0.64) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL14804379 | 0.86 | CCR1 (0.89) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL17051588 | 0.82 | CCR1 (0.57) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL26721041 | 0.82 | CCR1 (0.71) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL5612786 | 0.81 | CCR1 (0.61) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL14804380 | 0.80 | CCR1 (0.76) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL17051587 | 0.80 | CCR1 (0.59) | CCR1CCR5CCR8HDAC6METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| EP-2295428-A2 | Linear pyridazine and pyrrolic compounds, methods of preparation and applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | PPOX, PNPO, PLPBP | CCR1 3399/4885CCR5 997/4885CCR8 3114/4885 |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | CCR1 3696/4885CCR5 1706/4885CCR8 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.